AB257099

Human MAPK3 (ERK1) knockout HEK-293T cell lysate

Name: Human MAPK3 (ERK1) knockout HEK-293T cell lysate (ab257099) | Abcam
Brand: Abcam Limited
SKU: AB257099
Price: 113000 JPY
Availability: InStock

Be the first to review this product! Submit a review

(0 Publication)

MAPK3 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.

別名を表示する

ERK-1, ERT 2, Extracellular signal related kinase 1, Extracellular signal-regulated kinase 1, HGNC6877, HS44KDAP, HUMKER1A, Insulin-stimulated MAP2 kinase, MAP Kinase, MAP kinase 1, MAP kinase 3, MAP kinase isoform p44, MAPK, MAPK 1, MGC20180, MK03_HUMAN, Microtubule-associated protein 2 kinase, Mitogen-activated protein kinase 1, Mitogen-activated protein kinase 3, OTTHUMP00000174538, OTTHUMP00000174541, PRKM 3, Protein Kinase Mitogen Activated 3, p44-ERK1, p44-MAPK

3 Images

Lab

Western blot - Human MAPK3 (ERK1) knockout HEK-293T cell lysate (AB257099)

Lane 1 : Wild-type HEK-293T cell lysate (20µg)

Lane 2 : MAPK3 knockout HEK-293T cell lysate (20µg)

Lanes 1- 2 : Merged signal (red and green). Green - ab109282 observed at 43 kDa. Red - loading control ab8245 observed at 37 kDa.

ab109282 Anti-ERK1 antibody [EP4967] was shown to specifically react with ERK1 in wild-type HEK-293T cells in western blot. Loss of signal was observed when knockout cell line ab266519 (knockout cell lysate ab257099) was used. Wild-type and ERK1 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab109282 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4^°C at 1 in 1000 and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye^® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye^® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-ERK1 antibody [EP4967] (<a href='/products/primary-antibodies/erk1-antibody-ep4967-ab109282'>ab109282</a>) at 1/1000 dilution

Lane 1:

Wild-type HEK-293T cell lysate at 20 µg

Lane 2:

MAPK3 knockout HEK-293T cell lysate at 20 µg

Lane 2:

Western blot - Human MAPK3 (ERK1) knockout HEK-293T cell line (<a href='/products/cell-lines/human-mapk3-erk1-knockout-hek-293t-cell-line-ab266519'>ab266519</a>)

Predicted band size: 43 kDa

Observed band size: 43 kDa

false

Lab

Western blot - Human MAPK3 (ERK1) knockout HEK-293T cell lysate (AB257099)

Lane 1 : Wild-type HEK-293T cell lysate (20µg)

Lane 2 : MAPK3 knockout HEK-293T cell lysate (20µg)

Lanes 1- 2 : Merged signal (red and green). Green - ab32537 observed at 43 kDa. Red - loading control ab8245 observed at 37 kDa.

ab32537 Anti-ERK1 antibody [Y72] was shown to specifically react with ERK1 in wild-type HEK-293T cells in western blot. Loss of signal was observed when knockout cell line ab266519 (knockout cell lysate ab257099) was used. Wild-type and ERK1 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab32537 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4^°C at 1 in 1000 and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye^® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye^® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-ERK1 antibody [Y72] (<a href='/products/primary-antibodies/erk1-antibody-y72-ab32537'>ab32537</a>) at 1/1000 dilution

Lane 1:

Wild-type HEK-293T cell lysate at 20 µg

Lane 2:

MAPK3 knockout HEK-293T cell lysate at 20 µg

Lane 2:

Western blot - Human MAPK3 (ERK1) knockout HEK-293T cell line (<a href='/products/cell-lines/human-mapk3-erk1-knockout-hek-293t-cell-line-ab266519'>ab266519</a>)

Predicted band size: 43 kDa

Observed band size: 43 kDa

false

Sanger Sequencing - Human MAPK3 (ERK1) knockout HEK-293T cell lysate (AB257099)

Sanger seq

Unknown

Sanger Sequencing - Human MAPK3 (ERK1) knockout HEK-293T cell lysate (AB257099)

Homozygous : 1 bp deletion in exon1

Key facts

細胞タイプ

HEK-293T

生物種

Human

組織

Kidney

ノックアウト検証方法

Sanger Sequencing,Western blot

ノックアウト変異

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

style

left-column

製品の詳細

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

style

left-column

製品内容

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257099-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human MAPK3 knockout HEK293T cell lysate", "number":"AB257099-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HEK293T cell lysate", "number":"AB257099-CMP02", "productcode":"" } ] } } }

style

left-column

出荷温度及び保存条件

遺伝子名

MAPK3

遺伝子編集のタイプ

Knockout

遺伝子編集の方法

CRISPR technology

ノックアウト検証方法

Sanger Sequencing, Western blot

出荷温度

Ambient - Can Ship with Ice

短期保存温度

-20°C

長期保存温度

-20°C

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

ERK1 also known as MAPK3 is an extracellular signal-regulated kinase involved in transmitting signals from the cell surface to the nucleus. This protein has a molecular mass of about 44 kDa. ERK1 expresses in various tissue types with higher expression in the brain heart and skeletal muscle. Researchers often study ERK1 in the context of its role in cellular signaling due to its involvement in critical regulatory functions.

Biological function summary

ERK1 plays a significant role in cell cycle regulation differentiation and proliferation. It forms part of the MAPK signaling cascade becoming activated through a phosphorylation event. In its activated form ERK1 translocates to the nucleus where it phosphorylates target substrates. ERK1 often functions in conjunction with its homolog ERK2 to mediate these cellular processes marking it as an essential player in growth factor signaling.

Pathways

ERK1 functions primarily within the MAPK/ERK signaling pathway a major conduit for transmitting proliferative signals from growth factor receptors. ERK1 interacts with proteins like MEK1/2 which phosphorylate and activate ERK1 in response to extracellular stimuli. Another critical pathway involving ERK1 is the Ras-Raf-MEK-ERK cascade which regulates various cellular outcomes. This connection to the Ras family highlights its importance in signal transduction and reinforces its position in critical cellular processes.

Aberrant activation of ERK1 connects to diseases such as cancer and cardiovascular disorders. In cancer the dysregulation of the MAPK/ERK pathway often through mutations affecting Ras or Raf proteins leads to uncontrolled cell proliferation. ERK1's involvement in cardiovascular diseases links to its role in hypertrophic signaling in cardiac cells where altered ERK1 activity can contribute to pathological cardiac remodeling. Understanding these interactions can aid in developing therapeutic strategies targeting the MAPK/ERK signaling pathway.

style

left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style

left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style

left-column

製品プロトコール

Visit the General protocols
Visit the Troubleshooting

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Human MAPK3 (ERK1) knockout HEK-293T cell lysate